Group items tagged

Clove Dental started its journey with a clear vision to provide highest quality dental care across the country. Clove offers a comprehensive set ..

MarksMan Healthcare Communications, one of the renowned and eminent organizations in the healthcare space offers Health Economics and Outcomes Research

In our special issue of "The 10 Leading Diagnostic Solution Providers 2019", we have featured top diagnostic companies that have not only enabled correct...

Ochsner is led by the President and CEO, Warner Thomas - a leader with a strategic vision. He exemplifies courage in a time of change to ensure that the organization positively embraces disruption and continues to move in the right direction that is best for its patients.

There is a lack of an objective point-of-injury (POI) or point-of-care (POC) test. TBI testing today is symptomatic diagnosis, which has a high error rate..

Biolumo's flagship product is a fast, point-of-care antibiotics selection device for general practitioners and clinics. The company is offering diagnostic..

Medcloud is a patient-centered platform for diagnosis, focused on simplifying test management in all its phases. Unlike other medical imaging solutions..

Driven with the passion of 'Making diagnostic lab tools accessible to everyone', Colorimetrix was established in 2014, and officially started commercial...

The medical diagnostics industry is advancing at a fast-paced. The new innovations come with a promise to enhance the accuracy of detecting diseases...

Molecular diagnostics has the potential to aid early detection and diagnosis of diseases as deadly as cancer and the further advancements...

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report

The global dental implant market size was valued at USD 3.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.0% from 2021 to 2028.

To help pharmacy owner to better understand the negotiating process, Community Pharmacy England (CPE) has published commentary and infographics. "Our work to negotiate fair funding, as well as changes to NHS pharmacy services, with the Department of Health and Social Care (DHSC) and NHS England is a crucial part of our role," said CPE. "Understandably the sector is eagerly awaiting an update on the progress of the current negotiations on the Government's pledge to invest £645m in community pharmacies and, as part of our ongoing efforts to improve transparency of our work, we have released materials to explain the negotiating process." Negotiating Team Member Stephen Thomas - who joined the team this year - has written a blog about his experiences. He has described both the complexity of the process and volume of work undertaken, and recognises the significance of his role on behalf of pharmacy owners across the country. Whilst speed is of the essence, even higher on the Negotiating Team's list of priorities is working through a large number of important questions - particularly around the funding and logistics that need to be put in place.

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document published by Nuffield Trust and The King's Fund has revealed. It says community pharmacies in England must adapt to changing population needs amidst unprecedented health and care challenges. Commissioned by Community Pharmacy England, the report titled 'A Vision for Community Pharmacy', published on Sept. 19, is a result of almost a year of research and extensive consultation with the sector and wider stakeholders, advocating for community pharmacy. The think tanks detail a shift in the community pharmacy sector, highlighting how pharmacies can contribute to crucial policy objectives regarding population health, prevention, and the increasing demand in primary care. "The health and care needs of the population are evolving, and pharmacies in England, like all components of the health and care system, must adjust to address these changes," said Helen Buckingham, Director of Strategy at Nuffield Trust.

The Company Chemists' Association (CCA) has highlighted a worrying trend of increasing numbers of pharmacy closures in England, which is disproportionately affecting the most deprived communities in the country. With 338 more pharmacies closed this year, an average of eight pharmacies closed per week, there has been a net loss of 1,008 pharmacies in England since 2015, the CCA said. Between 2015 and June 2023, maximum number of pharmacies were closed in the 20 per cent most deprived neighbourhoods of the country, with 37.5 per cent of the total closures occurring in Indices of Multiple Deprivation deciles 1 and 2. The association has raised concern that "permanent closures will undermine healthcare accessibility in deprived areas, where access tends to be more limited despite greater need."

The Health and Social Care Select Committee (HSCC) on Tuesday held the first session in their pharmacy inquiry, with a panel of experts discussing the key issues facing community pharmacies in the country. Representatives from community pharmacy associations highlighted some of their biggest challenges and their vision for the future, as well as actions that government and NHS England can take to address those challenges for a better future for the sector. Opening the session, the Committee's vice-chair, Rachel Maskell MP, asked the representatives if they felt the government was ambitious enough in what it believes community pharmacy can do to address NHS pressures, or are pharmacists being held back by issues around workforce funding, contracting, and technological changes. Malcolm Harrison, Chief Executive, Company Chemists' Association (CCA), expressed that the government is not ambitious enough, saying "there's always opportunity to be more ambitious".

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.

When Ignasi Biosca-Reig heard there were shortages of amoxicillin in Spain, he quickly added shifts at his drug company's factories to boost production of the popular antibiotic. But a few extra shifts was as far as he could go. Much as he would have liked to significantly increase supplies, Biosca-Reig said he couldn't justify investing millions of euros in new production lines unless he was paid more for the generic drug to cover sharply rising costs. But, like many other European countries, Spain set the price manufacturers are paid for paediatric amoxicillin when the generic version of the drug was first launched in the country two decades ago, and it has barely budged since. "It's a non-business," said Biosca-Reig, chief executive of Spanish drugmaker Reig Jofre. "We wanted to react, but we had a problem," he said. "The costs go up, the price remains the same."

New data published by NHS England on Thursday (4 January) showed that more than 31.4 million GP appointments (excluding vaccinations) were delivered in November 2023. This is four million more than the number recorded in the same month before the pandemic, and is considered the busiest November on record for GP teams. Compared to the previous month (October 2023), 3.3 per cent more appointments were booked and attended on the same day in November. Almost seven in ten patients attended their appointments within seven days of booking, an increase of 4.5 per cent from the previous month.